Significant advances have been made in recent years to develop therapeutic agents beyond the "blunderbuss" approach of broadly targeting all rapidly dividing cells, to ones that better target tumor ...

Driven by the success of 14 approved antibody drug conjugates (ADCs) and a promising developmental pipeline, the field of ADCs has gained significant traction and are anticipated to capture a notable ...

Cancer has been one of the most persistent diseases modern medicine has faced. Treatments are often tricky to develop as doctors and researchers have to differentiate between healthy and cancerous ...

The growing popularity and therapeutic potential of antibody drug conjugates (ADCs) is evident in the rapid growth in intellectual capital, financing and partnership activity reported in the past five ...

Chemotherapy is one of the most widely used cancer therapies; however, chemotherapy often causes serious side effects. Antibody-drug conjugates (ADCs) are promisingly emerging cancer therapies that ...

Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "Lymphoma Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2030" report has been added to ...

Antibody-drug conjugates (ADCs) represent an emerging class of therapeutics across solid tumor oncology and are already positioned as a cornerstone therapy for patients with urothelial carcinoma (UC).

Probody drug conjugates, immune-stimulating antibody conjugates, engineered toxin bodies, radioligand conjugates, and so on comprise the new wave of molecules in clinical development, seeking to ...

Beyond Anticancer Therapeutics: Polymer–Drug Conjugates for the Treatment of Diseases other than Cancer In the last decade, the field of polymer–drug conjugates has expanded towards novel therapeutic ...